Jazz Pharmaceuticals (JAZZ) EBT (2010 - 2026)

Jazz Pharmaceuticals' EBT history runs 17 years deep, the most recent figure standing at $299.2 million for Q1 2026.

• On a quarterly basis, EBT rose 372.5% year-over-year to $299.2 million in Q1 2026; TTM through Mar 2026 was -$218.8 million, a 160.43% decrease from a year earlier, with the FY2025 full-year figure at -$627.9 million, down 233.49% from the prior year.
• EBT rose to $299.2 million in Q1 2026 per JAZZ's latest filing, from $208.5 million in the prior quarter.
• Across five years, EBT topped out at $299.2 million in Q1 2026 and bottomed at -$735.6 million in Q2 2025.
• The 5-year median for EBT is $55.1 million (2023), against an average of $3.9 million.
• Across the five-year window, EBT soared 771.16% in 2023 and plunged 6753.93% in 2025, its largest moves.
• Year by year, EBT stood at -$340.0 million in 2022, then jumped by 118.1% to $61.5 million in 2023, then surged by 116.52% to $133.2 million in 2024, then soared by 56.49% to $208.5 million in 2025, then jumped by 43.52% to $299.2 million in 2026.
• Per Business Quant, the three latest JAZZ EBT figures stand at $299.2 million (Q1 2026), $208.5 million (Q4 2025), and $9.0 million (Q3 2025).